Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to…
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term…
Suraj Estate Developers Reports Robust FY25 Performance with 33% Growth in Revenue and 48% Jump in PAT
MUMBAI, India, May 29, 2025 /PRNewswire/ -- Suraj Estate Developers Ltd. today…
KBRA Affirms and Withdraws Rating for Fortegra Financial Corp, Assigns Ratings for The Fortegra Group, Inc., and Fortegra Specialty Insurance Company, and Affirms Ratings for Debt and Fortegra’s Key Insurance Subsidiaries
NEW YORK--(BUSINESS WIRE)--#creditratingagency--KBRA assigns an issuer rating of BBB to The Fortegra…